NCT00362648View on ClinicalTrials.gov

Developing World Study for RotaTeq™ (V260-015)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

7,504

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
VomitingDiarrheaFever
Interventions
BIOLOGICAL

RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent

2.0 mL oral dose of RotaTeq™. 14 week treatment period

BIOLOGICAL

Comparator: Placebo

Arm 2: Placebo. 14 week treatment period

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00362648 - Developing World Study for RotaTeq™ (V260-015)(COMPLETED) | Biotech Hunter | Biotech Hunter